Kolon TissueGene (950160.KQ) Q1 2026: ₩99.9B Net Loss Is 95% Non-Cash Derivatives as TG-C Phase 3 Misses Primary Endpoints
The accounting headline masks a stabilizing cash burn — but ₩355.8 billion in capitalized development costs now faces its most consequential impairment test as the second Phase 3 readout approaches in October.
Source: Q1 2026 Quarterly Report (28th Fiscal Year, January 1 – March 31, 2026) — Filed May 15, 2026 with DART | Standalone (Non-Consolidated) Financial Statements; no consolidated statements exist as the company has no subsidiaries | Functional and Presentation Currency: USD; ₩ figures translated at period-end rate (balance sheet) and average rate (income statement / cash flows) | Unit: ₩ billions
A Note on Subsequent Events — Read This First
This analysis is based on the Q1 2026 quarterly filing (submitted May 15, 2026), but a development of decisive importance has since become public. On May 8, 2026, Kolon TissueGene released topline results from the first of two U.S. Pivotal Studies for TG-C (Invossa) in knee osteoarthritis. The primary endpoints — WOMAC joint function score and VAS pain score — failed to achieve statistical significance versus placebo, with an unusually durable placebo response persisting through the full 24-month observation window. On July 21, 2026, the company described the outcome as "half a success," outlined plans to revise its FDA approval strategy, and acknowledged that commercialization would be delayed. The second Pivotal Study topline is scheduled for October 2026. As a consequence, the impairment risk attached to the ₩355.8 billion development cost asset — examined throughout this report — is no longer a theoretical future scenario. Whether it materializes within the next two to three reporting periods depends on the October dataset and the subsequent FDA consultation.
